Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:

Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5395_Библиотеки_им_академика_М_И_Перельмана

.pdf
Скачиваний:
0
Добавлен:
15.09.2026
Размер:
15 Мб
Скачать
☆
Contributors
https://t.me/medicina_free
Sara Badr Department of Chemical System Engineering, The University of Tokyo, Tokyo, Japan
Massimiliano Barolo CAPE-Lab—Computer-Aided Process Engineering Labora­tory, University of Padova, Padova, Italy
Paul I. Barton Process Systems Engineering Laboratory, Massachusetts Institute of Technology, Cambridge, MA, USA
Mohammad Amin Boojari Biotechnology Group, Faculty of Chemical Engineer­ing, Tarbiat Modares University, Tehran, Iran
Richard D. Braatz Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA
Daniel Casas-Orozco Davidson School of Chemical Engineering, Purdue Univer­sity, West Lafayette, IN, USA
Pierre-François Chavez UCB Pharma, Braine l’Alleud, Belgium
Giorgio Colombo Process and Systems Engineering Centre (PROSYS), Depart-
ment of Chemical and Biochemical Engineering, Technical University of Denmark, Kgs. Lyngby, Denmark
Abina M. Crean University College Cork, Cork, Ireland
Ashok Das Department of Mathematics, Indian Institute of Technology Kharagpur,
Kharagpur, West Bengal, India
Francesco Destro CAPE-Lab—Computer-Aided Process Engineering Laboratory, University of Padova, Padova, Italy
Tump a D e y Faculty of Engineering and Science, School of Science, University of Greenwich, Kent, UK CIPER—Centre for Innovation and Process Engineering Research, Kent, UK
xi
xii Contributors
https://t.me/medicina_free
Dennis Douroumis Faculty of Engineering and Science, School of Science, Uni­versity of Greenwich, Kent, UK CIPER–Centre for Innovation and Process Engineering Research, Kent, UK
Julie Fahier UCB Pharma, Braine l’Alleud, Belgium
Mohammad Fakroleslam Process Engineering Department, Faculty of Chemical
Engineering, Tarbiat Modares University, Tehran, Iran
Zhenguo Gao Tianjin University, Tianjin, China
Krist V. Gernaey Process and Systems Engineering Centre (PROSYS), Depart-
ment of Chemical and Biochemical Engineering, Technical University of Denmark, Kgs. Lyngby, Denmark
J. Glassey School of Engineering, Newcastle University, Newcastle upon Tyne, UK
Parag Gogate Chemical Engineering Department, Institute of Chemical Technol-
ogy, Mumbai, India
Junbo Gong Tianjin University, Tianjin, China
Matteo Grossi Process and Systems Engineering Centre (PROSYS), Department
of Chemical and Biochemical Engineering, Technical University of Denmark, Kgs. Lyngby, Denmark
Izumi Hirasawa Department of Applied Chemistry, Waseda University, Tokyo, Japan
Yashraj Jagtap Chemical Engineering Department, Institute of Chemical Technol­ogy, Mumbai, India
Mark Nicholas Jones Process and Systems Engineering Centre (PROSYS), Department of Chemical and Biochemical Engineering, Technical University of Denmark, Kgs. Lyngby, Denmark
M. Karlberg School of Engineering, Newcastle University, Newcastle upon Tyne, UK
Brian M. Kerins University College Cork, Cork, Ireland
A. Kizhedath School of Engineering, Newcastle University, Newcastle upon Tyne,
UK
Jitendra Kumar Department of Mathematics, Indian Institute of Technology Kharagpur, Kharagpur, West Bengal, India
Daniel J. Laky Davidson School of Chemical Engineering, Purdue University, West Lafayette, IN, USA
Corentin Larcy UCB Pharma, Braine l’Alleud, Belgium
Contributors xiii
https://t.me/medicina_free
Seyed Soheil Mansouri Process and Systems Engineering Centre (PROSYS), Department of Chemical and Biochemical Engineering, Technical University of Denmark, Kgs. Lyngby, Denmark
Christos T. Maravelias Andlinger Center for Energy and the Environment and Department of Chemical and Biological Engineering, Princeton University, Prince­ton, NJ, USA
Ikuma Masaki Department of Applied Chemistry, Waseda University, Tokyo, Japan
Kensaku Matsunami Department of Chemical System Engineering, The Univer­sity of Tokyo, Tokyo, Japan
Shamik Misra Department of Chemical and Biological Engineering, University of Wisconsin, Madison, WI, USA
Zoltan K. Nagy Davidson School of Chemical Engineering, Purdue University, West Lafayette, IN, USA
Uttom Nandi Faculty of Engineering and Science, School of Science, University of Greenwich, Kent, UK CIPER—Centre for Innovation and Process Engineering Research, Kent, UK
Morteza Nikkhah Nasab Process Systems Engineering Laboratory, Department of Chemical Engineering, AmirKabir University of Technology (Tehran Polytechnic), Tehran, Iran
Anastasia Nikolakopoulou Massachusetts Institute of Technology, Cambridge, MA, USA
Mehrdad Pasha UCB Pharma, Braine l’Alleud, Belgium
Mayur M. Patel Department of Pharmaceutics, Institute of Pharmacy, Nirma Uni-
versity, Ahmedabad, India
Michael Patrascu Department of Chemical Engineering, Technion-Israel Institute of Technology, Haifa, Israel
Simone Perra Process and Systems Engineering Centre (PROSYS), Department of Chemical and Biochemical Engineering, Technical University of Denmark, Kgs. Lyngby, Denmark
Gabrielle Pilcer UCB Pharma, Braine l’Alleud, Belgium
Gintaras V. Reklaitis Davidson School of Chemical Engineering, Purdue Univer-
sity, West Lafayette, IN, USA
Ali M. Sahlodin Process Systems Engineering Laboratory, Department of Chem­ical Engineering, AmirKabir University of Technology (Tehran Polytechnic), Tehran, Iran
xiv Contributors
https://t.me/medicina_free
Chinmayee Sarode Chemical Engineering Department, Institute of Chemical Tech­nology, Mumbai, India
Seyed Abbas Shojaosadati Biotechnology Group, Faculty of Chemical Engineer­ing, Tarbiat Modares University, Tehran, Iran
Fanny Stauffer UCB Pharma, Braine l’Alleud, Belgium
Hirokazu Sugiyama Department of Chemical System Engineering, The University
of Tokyo, Tokyo, Japan
Isuru Udugama Process and Systems Engineering Centre (PROSYS), Department of Chemical and Biochemical Engineering, Technical University of Denmark, Kgs. Lyngby, Denmark
Joi Unno Department of Applied Chemistry, Waseda University, Tokyo, Japan
Preksha Vinchhi Department of Pharmaceutics, Institute of Pharmacy, Nirma
University, Ahmedabad, India
Matthias von Andrian Massachusetts Institute of Technology, Cambridge, MA, USA
Lifang Zhou Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA
Xiaoxiang Zhu Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA
Process Control and Intensification
https://t.me/medicina_free
of Solution Crystallization
Junbo Gong and Zhenguo Gao
Solution crystallization attracts more and more attention in the pharmaceutical industries because of the functions of separation and the tuning ability of solid-state properties at the molecular level. Generally, the research of solution crystallization includes crystal engineering and crystallization process design and control. The crystallization process design and control have achieved great progress in the past decade, in which process analytical technology (PAT) has come to the real manu­facturing practice and the conversion from batch to continuous is becoming a clear tendency. In this chapter, the design and optimization of the crystallization process are summarized that covers process control, seeding technique, intensification by external fields, and the solution crystallization in continuous manufacturing.
1 Solution Crystallization Process Control
1.1 Introduction of Solution Crystallization Process Control
As a unit operation for separating and purifying solid products, crystallization is widely used in the fields of medicine, food, microelectronics, and fine chemicals. The crystallization process determines the purity, morphology, polymorph, particle size, and particle size distribution of the solid product and many other character­istics, which have a significant impact on the performance of the drug and the efficiency of the post-processing process [1]. Therefore, the precise control of the crystallization process is of great significance to the production process and the quality of products.
J. Gong ()·Z.Gao Tianjin University, Tianjin, China e-mail: junbo_gong@tju.edu.cn
© The Author(s), under exclusive license to Springer Nature Switzerland AG 2022 A. Fytopoulos et al. (eds.), Optimization of Pharmaceutical Processes, Springer Optimization and Its Applications 189, https://doi.org/10.1007/978-3-030-90924-6_1
1
2 J. Gong and Z. Gao
https://t.me/medicina_free
Fig. 1 A high-level overview of the efficient combination of model-free and model-based QbC approaches for rapid (model-free) and optimal (model-based) crystallization process design. (Caption and figure reprinted with permission from Ref. [5]
The actual purpose of crystallization control is to govern the crystal nucleation and growth. Based on modeling and experimental methods, there are a lot of researches on the control of polymorph, shape, and size [2–4]. The control of the crystallization process usually aims to control the crystallization path in a safe operation zone that ensures a robust manufacturing process. The crystallization control strategies can be divided into two major categories: model-free and model­based control approaches. Model-free techniques are based on feedback control algorithms relying on in situ PAT measurements that provide the critical quality attributes of the product, including size distribution, crystal shape, fewer impurities, and target crystal form. Model-based control involves using a mathematical model and numerical simulation to design the process by solving process optimization problems. Nagy [5] proposed a general framework for the optimal design of crystallization processes, which combined the application of two QbC methods: model-free (mfQbC) and model-based (mbQbC). In addition to its robust operating procedures, mfQbC also automatically generates model parameters and experimen­tal data required by the mbQbC. As shown in Fig. 1, the derived model can be used for optimal crystallization process design.
For a classical cooling crystallization process, the mfQbC includes the following main steps: first, cooling-holding-heating experiments under different heating rates
Process Control and Intensification of Solution Crystallization 3
https://t.me/medicina_free
and cooling rates, these experiments provide the nucleation rate and solubility kinetics. In the second step, the direct nucleation control (DNC) experiment obtains the width of the metastable zone of primary nucleation and secondary nucleation. The third step is to guide the supersaturation control (SSC) experiment according to the crystal phase diagram obtained from the DNC experiment to obtain the tem­perature control curve. Finally, to be easily implemented in an industrial distributed control system, the temperature curve generated by the SSC is approximated by a linear ramp to obtain the given temperature curve designed by mfQbC. The process control technology plays an increasingly important role in the controlling of product polymorph, purity, shape, particle size, and particle size distribution.
1.2 Polymorphic Control
Drug polymorphism refers to two ormore molecular assembly modes when the drug molecules crystallize from solution to solid state [6]. Polymorphism is a common phenomenon in the crystallization process. Since the different crystal forms of the drug may seriously affect the stability, bioavailability, therapeutic effect, and product quality, so ensuring the consistency of the crystal form is crucial to the drug production process. There are challenges in polymorphic control, for example, the transformation of the crystal form will lead to difficult control of the polymorphism in which the purity of the crystal form is hard to control during the production process.
In response to the challenge of polymorphic control, feedback control strategies provide a pathway for solving the difficulties in the control process. The control of polymorphs in the crystallization process mainly controls the nucleation of nontarget crystals and promotes the growth of target crystals. For polycrystalline materials, different ways to produce supersaturation may result in different crystal forms. Supersaturation is the driving force of the crystallization process, and many researchers have shown that an optimal supersaturation exists for a crystallization process, and various methods for supersaturation measurement and implementation of constant SSC strategy have been investigated. The SSC control strategy is based on the understanding that the crystallization process needs to be operated in the metastable region in the phase diagram, as shown in Fig. 2a. This method can specify an arbitrary concentration target curve in the phase diagram, which is particularly useful for the control of the polymorphic crystallization process. In the polymorphic crystallization process, a complex operation trajectory is designed to selectively control a specific crystal form [7]. Besides, setting the operation trajec­tory in the crystallization phase diagram can greatly reduce the sensitivity of the crystal size distribution to process disturbances and can prevent the crystallization process crossing the metastable zone and causing undesired explosion nucleation. The advantage of this method is that by specifying the operation trajectory in the crystalline phase diagram, the best operation trajectory in the time domain (such as
4 J. Gong and Z. Gao
https://t.me/medicina_free
Fig. 2 Crystallization phase diagram (a); supersaturation and corresponding temperature profiles obtained during the SSC process (b)
the cooling curve) is automatically determined, and it can be implemented on an industrial scale through a standard tracking control system.
By using traditional open-loop control approaches to implement the cooling profile, such as simple linear cooling, it is hard to maintain the concentration operating curve along with an expected trajectory. The SSC is a higher-level control approach through controlling the crystallization operating trajectory in the phase diagram than controlling the process by just following the timely determined temperature profile (or solvent/anti-solvent ratio). The main advantage of this approach over uncontrolled crystallization is that the operating curve can be directly maintained within a “robust operating zone,” which can represent the nucleation metastable zone or the targeted polymorph nucleation/growth region. In this way, SSC can avoid undesired nucleation and polymorph transformation and achieve optimal crystallization performance without a large number of experiments for investigating the influence mechanism of process conditions [8–10]. The schematic representation of the SSC approach is shown in Fig. 2b.
The SSC strategy can directly control the crystallization process on the phase diagram, which is a relatively intuitive control method. However, when the crys­tallization phase diagram is greatly affected by disturbances or the nucleation rate is high, the robustness of this method will be greatly reduced [11]. In addition, the concentration feedback control strategy cannot directly control the properties of solids, which means that even if the supersaturation levels of the two batches are the same in the batch process, the product properties may still be quite different due to process disturbances.
The temperature cycle during the crystallization process is beneficial to dissolve the metastable crystal form produced during the crystallization process. Pataki et al. [12] used Raman to detect nontarget crystal forms in the crystallization process and trigger automatic heating to dissolve and eliminate metastable crystal forms. Tacsi et al. [13] adopted polymorph concentration control to separately refine two crystal
Process Control and Intensification of Solution Crystallization 5
https://t.me/medicina_free
forms of carvedilol. During the crystallization process, Raman detected a nontarget crystal form to trigger temperature-rising dissolution, and the products obtained were all target crystal forms. Active polymorphic feedback control realizes the refining of the stable crystal form of OABA in the case of impure seed crystal form. Raman detects that the metastable crystal form triggers heating and dissolution, and then the system performed supersaturation control to prepare stable crystals [14].
In the past 20 years, in situ monitoring of polymorphism in the crystallization process has developed rapidly, including online Raman, in situ XRD, in situ laser backscattering, and in situ process image microscopy. Although none of these technologies can be applied to all solute-solvent systems for online monitoring of polymorphs, for most systems, at least one sensor technology can be used to monitor the conversion between different crystal forms [15]. In recent years, process detection and online analysis methods have been widely used in polymorphic selective crystallization processes. Based on this, the development of polymorphic feedback control (or closed-loop control) strategies has also made continuous progress.
1.3 CSD and Morphology Control
In industrial crystallization process, crystal morphology, crystal size, and crystal size distribution (CSD) are important properties of crystals, because these properties play a vital role in determining the quality of the final product and the efficiency of downstream processes. Also, a poor particle size distribution may lead to solvent entrainment, and then leading to impurity problems, resulting in a reduced purity. The process control technology is playing an increasingly important role in improving yield and purity, ensuring the consistency of crystal products in terms of particle size and crystal morphology, and avoiding particle coalescence and solvent encapsulation.
Generally, the explosion nucleation process will promote the crystallization process to produce fine particles, and the dissolution process will be the dissolution of fine particles. Therefore, the heating-cooling cycle can eliminate fine crystals and prepare larger crystals. The DNC strategy is based on the idea that the smaller the system particles, the larger the product particle size and the temperature cycle is beneficial to eliminate fine crystals. The DNC strategy shows good consistency in the crystallization process, because this method does not need to know the crystallization process model, kinetics, and the width of the metastable zone in advance, and these parameters change due to the hydrodynamic properties during the amplification process. Changes often occur, so it is a robust feedback control strategy. When the number of monitored crystal count changes, DNC automatically adjusts the operating conditions, which can well overcome the adverse effects of process disturbances. The most significant feature of the DNC strategy is the ability to directly monitor and control the crystal properties, which can be achieved through a controllable growth and dissolution cycle (cooling/heating cycle or anti-
6 J. Gong and Z. Gao
https://t.me/medicina_free
Fig. 3 Schematic working of ADNC approach (a); effect of temperature cycling on a crystal suspension (b) (Caption and figure reprinted with permission from Ref. [19]
solvent/solvent addition cycle). The advantage of DNC is that it can produce crystal products with a more regular particle size in line with expectations [16], reduce particle coalescence and solvent occlusion [17], and improve the purity of crystal [18]. This is because the direct nucleation control can inhibit the adsorption of impurities on the crystal surface by repeatedly dissolving the growth cycle, and the fine particles and impurities on the crystal surface will dissolve continuously during the heating process. Thus, in the subsequent cooling process, crystal growth is promoted, and the crystal with a larger particle size has a smaller specific surface area, which reduces the adsorption of impurities on the surface, as shown in Fig. 3.
The DNC nucleation strategy is also suitable for anti-solvent crystallization. Nagy et al. [20] used the DNC strategy to control the CSD of glycine by controlling the flow of solvent and anti-solvent. Most of the crystallization process indirectly affects CSD through real-time temperature control or anti-solvent to follow the supersaturation set in the phase diagram. Using the SSC strategy during the crystallization process can keep the supersaturation constant at the set value, and reduce or avoid secondary nucleation during the entire crystallization process to promote crystal growth. And the image analysis-based direct nucleation control method based on image processing has a very significant effect on the control of